Lv4
480 积分 2023-05-26 加入
NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
2个月前
已完结
Direct-to-Biology Enabled Molecular Glue Discovery
2个月前
已完结
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors
2个月前
已完结
A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment
2个月前
已完结
In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities
2个月前
已完结
Antibody Conjugation of a Chimeric BET Degrader Enables in vivo Activity
3个月前
已完结
Degrader–Antibody Conjugates: Emerging New Modality
3个月前
已完结
Degrader-antibody conjugates
3个月前
已完结
Structure-Based Design of “Head-to-Tail” Macrocyclic PROTACs
4个月前
已完结
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
4个月前
已完结
皖公网安备34019202002308
